Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's.

Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser ...

The presence of three copies of chromosome 21, which harbors the amyloid precursor protein (APP) gene, is the most common genetic cause of Alzheimer’s disease. Carriers of this alteration have Down ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

Today, Biogen and Eisai announced they would terminate the Phase 3 ENGAGE and EMERGE trials of aducanumab for early Alzheimer’s disease. A futility analysis run by an independent data-monitoring ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

Researchers have devised a new way to sneak therapeutic cargo across the blood-brain barrier. Into the constant region of a human IgG1 antibody, they slid a domain that latches onto receptors that ...

After months of uncertainty, the hammer fell for Biogen: In a draft decision released January 11, the Centers for Medicare and Medicaid Services proposed to cover the anti-amyloid antibody Aduhelm ...

Scientists the world over are shocked and saddened to learn that John Q. Trojanowski passed away on February 8, at the altogether too-young age of 75. The cheerful and unmovable object to the ...

After decades of nonstarters, blood tests for Alzheimer’s disease are finally here, enabling researchers to predict who may have amyloid plaques in their brain. Among the candidate tests jostling for ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...